This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker Stock Might Rise From the Launch of Dimension Nexus AFM
by Zacks Equity Research
BRKR launches the Dimension Nexus AFM at the 2024 MRS Fall Meeting & Exhibit, expanding its Dimension AFM product line.
New Strong Sell Stocks for November 21st
by Zacks Equity Research
BATRA, BAX and BRKR have been added to the Zacks Rank #5 (Strong Sell) List on November 21, 2024.
New Strong Sell Stocks for November 12th
by Zacks Equity Research
BRKR, CMC and CNXC have been added to the Zacks Rank #5 (Strong Sell) List on November 12, 2024.
BRKR Stock Declines Despite Launching EpicIF Technology for CellScape
by Zacks Equity Research
Bruker's new technology, EpicIF, is set to enhance the CellScape Precise Spatial Proteomics platform.
BRKR Misses on Q3 Earnings, Cuts '24 View, Stock Up in Aftermarket
by Zacks Equity Research
Bruker delivers robust revenue growth in the third quarter despite soft general market conditions.
Bruker (BRKR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Bruker (BRKR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bruker (BRKR) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of -1.64% and 0.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Mettler-Toledo (MTD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Mettler-Toledo (MTD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BRKR Stock to Gain From Newly Formed Bruker Spatial Biology Division
by Zacks Equity Research
Bruker announces the formation of the new Bruker Spatial Biology division.
BRKR Stock Might Gain From the Newly Launched OptoVolt Module
by Zacks Equity Research
At the Neuroscience 2024 conference, Bruker released its latest OptoVolt module, which seamlessly integrates with Ultima 2Pplus microscope and NeuraLight 3D SLM.
Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors
by Zacks Equity Research
BRKR acquires Dynamic Biosensors or DBS. DBS's unique products, along with BRKR's SPR portfolio, should help the latter establish a leading biosensors business.
Here's Why You Should Retain BRKR Stock in Your Portfolio Now
by Zacks Equity Research
Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.
Is the Options Market Predicting a Spike in Bruker (BRKR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.
Bruker (BRKR) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Consider Retaining Bruker Stock in Your Portfolio Now?
by Zacks Equity Research
BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.
Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia
by Zacks Equity Research
Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.
Bruker (BRKR) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Evaluate Bruker's (BRKR) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Bruker (BRKR) Partners With NovAliX to Boost Drug Discovery
by Zacks Equity Research
Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.
Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised
by Zacks Equity Research
Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.
Compared to Estimates, Bruker (BRKR) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Is the Options Market Predicting a Spike in Bruker (BRKR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.
Bruker (BRKR) Q2 Earnings Meet Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 0% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Mettler-Toledo and Bruker
by Zacks Equity Research
Mettler-Toledo and Bruker have been highlighted in this Industry Outlook article.
2 Instruments Stocks to Watch From a Prospering Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like MTD and BRKR are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.